{'fraction_non_alphanumeric': 0.029783393501805054, 'fraction_numerical': 0.0036101083032490976, 'mean_word_length': 5.562130177514793, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 2, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Interleukin 6 blockade-associated weight gain with abdominal enlargement in a patient with rheumatoid arthritis.

Tocilizumab (TCZ) is a humanized monoclonal antibody to the interleukin 6 (IL-6) receptor used primarily in the treatment of rheumatoid arthritis (RA). The efficacy of TCZ in patients with RA has been well established both in terms of clinical response as well as inhibition of structural joint damage. Adverse effects of TCZ include intravenous infusion and hypersensitivity reactions, infections, possible gastrointestinal perforations, and laboratory test abnormalities, particularly hepatic transaminase elevations, altered lipid profile, and neutropenia. Weight gain, although discussed as a potential adverse effect of IL-6 blockade, has not been reported as yet in TCZ-treated patients. Although a mild weight increase in RA patients treated with antiYtumor necrosis factor > (TNF->) agents has been previously shown, presumably as a result of decreased inflammation and/or improved well-being, we observed and report herein an RA patient with anomalous weight gain during TCZ treatment.